Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit . GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C.
在馬里蘭州蓋瑟斯堡，2024年12月02日 (環球新聞社) -- altimmune公司 (納斯達克: ALT)，一家臨床階段生物製藥公司，今天宣佈， Scott Harris博士，altimmune公司的首席醫療官，將在華盛頓特區舉行的第17屆肌少症、消瘦和 wasting 疾病學會國際會議的 Cachexia Regulatory & Trials Update Workshop 上發佈 pemvidutide 在肥胖治療中的第二階段 MOMENTUm 試驗的身體組成數據，並參加一個小組討論。
Details for the panel discussion are as follows:
小組討論的詳細信息如下:
| Title: | Muscle Wasting in Weight Loss Therapy |
| Session: | Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues |
| Presenter: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Friday, December 6, 2024 at 9:30 am ET |
| 職稱： | 體重減輕療法中的肌肉消耗 |
| 會議主題： | 在肥胖療法背景下解決肌肉消耗的治療方法與監管問題 |
| 報告人： | Scott Harris博士，altimmune公司首席醫療官。 |
| 日期/時間: | 2024年12月6日星期五上午9:30 |
About Altimmune
關於Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit .
altimmune是一家臨床階段生物製藥公司，專注於開發創新的下一代基於肽的治療藥物。該公司正在開發pemvidutide，一種GLP-1/胰高血糖素雙受體激動劑，用於治療肥胖和MASH。要了解更多信息，請訪問。
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
在領英上關注@Altimmune, Inc.
在Twitter上關注@AltimmuneInc
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
公司聯繫人：
Greg Weaver
首席財務官
電話：240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
投資者聯繫人：
Lee Roth
Burns McClellan
電話：646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
媒體聯繫：
Danielle Cantey
Inizio Evoke，生物技術公司
電話：619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR Verified individual.
此新聞發佈是由經過驗證的個人發佈的。
